 |
471 Diseases |  |
207 Trials |
|
207 Trials |  |
10577 News |  |
| «12...121122123124125126127128129130131132133» |
- everolimus / Generic mfg.
Enrollment closed: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 (clinicaltrials.gov) - Nov 8, 2012
P2, N=25, Active, not recruiting, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
Enrollment closed, Metastases: Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer (clinicaltrials.gov) - Nov 1, 2012
P2, N=50, Active, not recruiting, Sponsor: Translational Oncology Research International
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment change, Metastases: A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 31, 2012
P1, N=19, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=29 --> 19
- everolimus / Generic mfg.
Enrollment open: The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation (clinicaltrials.gov) - Oct 30, 2012
P3, N=40, Recruiting, Sponsor: Hospital Vall d'Hebron
N=29 --> 19 Not yet recruiting --> Recruiting
- | everolimus / Generic mfg.
Biomarker, New P2 trial, Metastases: NEORAD: Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus (clinicaltrials.gov) - Oct 25, 2012
P2, N=60, Recruiting, Sponsor: Association Pour La Recherche des Th
- | dovitinib (TKI258) / Novartis, Oncoheroes
New P1 trial, Metastases: Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer (clinicaltrials.gov) - Oct 24, 2012
P1, N=17, Completed, Sponsor: Queen Mary University of London
- Torisel (temsirolimus) / Pfizer, Zelboraf (vemurafenib) / Roche
Trial initiation date, Combination therapy, Metastases: Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (clinicaltrials.gov) - Oct 23, 2012
P1, N=114, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Initiation date: Jul 2012 --> Dec 2012
- || everolimus / Generic mfg.
New P3 trial: EXIST-3: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (clinicaltrials.gov) - Oct 23, 2012
P3, N=355, Recruiting, Sponsor: Novartis Pharmaceuticals
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma (clinicaltrials.gov) - Oct 23, 2012
P1, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2012 --> Dec 2012 Recruiting --> Active, not recruiting
- | everolimus / Generic mfg.
Trial completion: A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis (clinicaltrials.gov) - Oct 21, 2012
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
Trial withdrawal, Combination therapy: A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer (clinicaltrials.gov) - Oct 21, 2012
P2, N=0, Withdrawn, Sponsor: University of Kansas
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Herceptin (trastuzumab) / Roche
Enrollment change, Combination therapy: A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer (clinicaltrials.gov) - Oct 21, 2012
P2, N=0, Withdrawn, Sponsor: University of Kansas
Recruiting --> Withdrawn N=30 --> 0
- ||| everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy: Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Oct 21, 2012
P1/2, N=103, Active, not recruiting, Sponsor: Mayo Clinic
N=30 --> 0 Recruiting --> Active, not recruiting
- everolimus / Generic mfg.
New P3 trial: The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation (clinicaltrials.gov) - Oct 14, 2012
P3, N=40, Recruiting, Sponsor: Hospital Vall d'Hebron
- | New P4 trial: Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation (clinicaltrials.gov) - Oct 11, 2012
P4, N=60, Completed, Sponsor: Yonsei University
- everolimus / Generic mfg., fluvastatin / Generic mfg., rosuvastatin / Generic mfg.
Trial completion: The Rosuvastatin In TrAnsplant Recipients Study (clinicaltrials.gov) - Oct 10, 2012
P4, N=20, Completed, Sponsor: University of Oslo School of Pharmacy
Recruiting --> Active, not recruiting Recruiting --> Completed
- Avastin (bevacizumab) / Roche
Enrollment closed, Surgery, Metastases: Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 9, 2012
P2, N=138, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Active, not recruiting
- everolimus / Generic mfg., erlotinib / Generic mfg.
Enrollment closed: RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (clinicaltrials.gov) - Oct 8, 2012
P2, N=17, Active, not recruiting, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Trial completion: Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (clinicaltrials.gov) - Oct 4, 2012
P3, N=184, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| Simulect (basiliximab) / Novartis, sotrastaurin (AEB071) / Novartis
Trial completion, Combination therapy: Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients (clinicaltrials.gov) - Oct 4, 2012
P2, N=175, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
New P1 trial, Metastases: Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer (clinicaltrials.gov) - Oct 2, 2012
P1, N=24, Recruiting, Sponsor: Cancer Research and Biostatistics Clinical Trials Consortium
- |||| everolimus / Generic mfg.
Enrollment open, Metastases: Everolimus Versus Placebo in Head and Neck Cancer (clinicaltrials.gov) - Oct 2, 2012
P2, N=160, Recruiting, Sponsor: University of Chicago
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- ||||| letrozole / Generic mfg., everolimus / Generic mfg.
New P2 trial, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 1, 2012
P2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
- everolimus / Generic mfg., sorafenib / Generic mfg.
Enrollment open: Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas (clinicaltrials.gov) - Sep 30, 2012
P1/2, N=118, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Trial completion: RAD: Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients (clinicaltrials.gov) - Sep 25, 2012
P3, N=719, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- everolimus / Generic mfg.
Enrollment open, Combination therapy: Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Sep 24, 2012
P1/2, N=125, Recruiting, Sponsor: University of Cologne
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| everolimus / Generic mfg.
Trial completion, Metastases: Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy (clinicaltrials.gov) - Sep 23, 2012
P2, N=160, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial initiation date: Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients (clinicaltrials.gov) - Sep 19, 2012
P4, N=60, Enrolling by invitation, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Sep 2012
- Enrollment open: Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients (clinicaltrials.gov) - Sep 19, 2012
P4, N=60, Enrolling by invitation, Sponsor: University of California, San Francisco
Initiation date: Jun 2012 --> Sep 2012 Not yet recruiting --> Enrolling by invitation
- everolimus / Generic mfg., gemcitabine / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride (clinicaltrials.gov) - Sep 17, 2012
P1/2, N=12, Completed, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Enrolling by invitation N=53 --> 12
- ||| retaspimycin (IPI-504) / Infinity Pharma
Enrollment change, Combination therapy: Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Sep 16, 2012
P1/2, N=70, Active, not recruiting, Sponsor: Infinity Pharmaceuticals, Inc.
N=53 --> 12 N=45 --> 70
- everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
Trial initiation date, Biopsy: Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium (clinicaltrials.gov) - Sep 12, 2012
P3, N=50, Recruiting, Sponsor: University of Miami
N=45 --> 70 Initiation date: Jul 2012 --> Nov 2012
- everolimus / Generic mfg., mycophenolate sodium / Generic mfg.
New P3 trial, Biopsy: Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium (clinicaltrials.gov) - Sep 5, 2012
P3, N=50, Recruiting, Sponsor: University of Miami
- | everolimus / Generic mfg.
New P2 trial: EVACEL: Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors (clinicaltrials.gov) - Sep 3, 2012
P2, N=72, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- Rituxan (rituximab) / Roche
Enrollment change: Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Sep 1, 2012
P1/2, N=70, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Initiation date: Jul 2012 --> Nov 2012 N=134 --> 70
- vorsetuzumab mafodotin (SGN-75) / Pfizer
New P1 trial, Combination therapy, Metastases: A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma (clinicaltrials.gov) - Aug 30, 2012
P1, N=4, Terminated, Sponsor: Seattle Genetics, Inc.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer (clinicaltrials.gov) - Aug 27, 2012
P2, N=41, Active, not recruiting, Sponsor: Hoosier Oncology Group
N=134 --> 70 Terminated --> Active, not recruiting
- || everolimus / Generic mfg.
New P3 trial: S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (clinicaltrials.gov) - Aug 26, 2012
P3, N=3500, Recruiting, Sponsor: Southwest Oncology Group
- everolimus / Generic mfg.
Biomarker, Enrollment open: A Study to Identify a Biomarker Predictive for Response on Everolimus in Solid Tumors (CPCT-03) (clinicaltrials.gov) - Aug 16, 2012
P=N/A, N=60, Recruiting, Sponsor: UMC Utrecht
Terminated --> Active, not recruiting Not yet recruiting --> Recruiting
- | Rituxan (rituximab) / Roche
New P2 trial: Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma (clinicaltrials.gov) - Aug 13, 2012
P2, N=60, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- JI-101 / Jubilant LifeSciences
Trial termination, Metastases: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=19, Terminated, Sponsor: University of Utah
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Lack of drug efficacy
- JI-101 / Jubilant LifeSciences
Enrollment change, Metastases: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=19, Terminated, Sponsor: University of Utah
Active, not recruiting --> Terminated; Lack of drug efficacy N=40 --> 19
- | everolimus / Generic mfg.
New P4 trial: Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population (clinicaltrials.gov) - Aug 9, 2012
P4, N=80, Recruiting, Sponsor: MARIO ABBUD FILHO
- Enrollment change, Metastases: Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel (clinicaltrials.gov) - Aug 8, 2012
P2, N=26, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
N=40 --> 19 N=56 --> 26
- Enrollment closed, Metastases: Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel (clinicaltrials.gov) - Aug 8, 2012
P2, N=26, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
N=56 --> 26 Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy: SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Aug 7, 2012
P2, N=25, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial completion: Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Aug 6, 2012
P1/2, N=40, Completed, Sponsor: Technische Universität München
Recruiting --> Active, not recruiting Recruiting --> Completed
- |||| bortezomib / Generic mfg., everolimus / Generic mfg.
Trial completion: PILLAR-1: Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy (clinicaltrials.gov) - Aug 1, 2012
P2, N=58, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- mitomycin / Generic mfg., everolimus / Generic mfg.
Enrollment change, Combination therapy, Metastases: S387: Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction (clinicaltrials.gov) - Aug 1, 2012
P1, N=16, Completed, Sponsor: Krankenhaus Nordwest
Active, not recruiting --> Completed N=21 --> 16
- mitomycin / Generic mfg., everolimus / Generic mfg.
Trial completion, Combination therapy, Metastases: S387: Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction (clinicaltrials.gov) - Aug 1, 2012
P1, N=16, Completed, Sponsor: Krankenhaus Nordwest
N=21 --> 16 Active, not recruiting --> Completed